Reduced benzodiazepine tolerance, but increased flumazenil-precipitated withdrawal in AMPA-receptor GluR-A subunit-deficient mice
Introduction
Benzodiazepine (BZ) treatment is widely used for quick and efficient anxiolytic and sedative responses. However, when the use is extended to longer periods, adverse effects emerge. These include tolerance to the initial drug effect, dependence as revealed by withdrawal symptoms after treatment discontinuation, and abuse problems (O'Brien, 2005, Rosenbaum, 2005).
γ-Aminobutyric acid type A (GABAA) receptors mediate the main effects of BZs (Korpi et al., 2002). BZs bind to the GABAA receptor and modulate their properties allosterically, which suggests that receptor adaptation could provide possible mechanisms for the development of tolerance and withdrawal symptoms. Many properties of the GABAA receptor complex have been observed to change during long-term BZ treatment. These include changes in the affinity and number of binding sites of BZs, altered receptor subunit composition, uncoupling of the BZ binding-site from the receptor channel function, and changes in the affinity and number of binding sites of GABA [for review, see Bateson, 2002, Hutchinson et al., 1996, Wafford, 2005]. Furthermore, GABAA receptor subunit-specificity has been suggested to have a role in the development of tolerance to BZs by downregulation of α5 subunit-containing receptors in the hippocampal dentate gyrus (Li et al., 2000, van Rijnsoever et al., 2004). Most of these studies have employed low to moderate doses of BZs, to which tolerance is quickly developed.
Other neurotransmitter systems have also been implicated as mechanisms underlying tolerance and dependence to BZs. Especially interesting is the main fast excitatory neurotransmission system in the brain using glutamate as the transmitter. It has been suggested that the BZ-induced increase in inhibitory transmission is counteracted by the glutamatergic system through modified glutamate metabolism and/or modified receptor mechanisms (Allison and Pratt, 2003, Izzo et al., 2001). When mice are chronically co-treated with BZs and an antagonist of N-methyl-d-aspartate (NMDA) receptors, tolerance develops only partially (Steppuhn and Turski, 1993). Development of tolerance to BZs increases mRNA of NMDA receptor NR1 and NR2B subunits, which can be reversed by NMDA receptor antagonist MK-801 (Almirón et al., 2004). Furthermore, withdrawal symptoms are reduced by the administration of NMDA and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists in a time-dependent manner: the former is effective when given at the time of withdrawal and the latter when given just prior to the appearance of the symptoms (Steppuhn and Turski, 1993). An increase in the number and activity of AMPA receptors in BZ tolerance is evidenced by increased binding of AMPA-receptor ligand [3H]Ro 48-8587 and by increased electrophysiological responses (Allison et al., 2005, Van Sickle and Tietz, 2002).
Importantly, the GluR-A (GluR-1) subunit of AMPA-type glutamate receptors has been implicated in neuroadaptational mechanisms, such as long-term potentiation (LTP), learning and memory and drug addiction (Bannerman et al., 2006, Carlezon and Nestler, 2002). During hippocampal synaptic plasticity, GluR-A subunit-containing receptors are targeted to the cell membrane, a pivotal event in LTP (Hayashi et al., 2000, Shi et al., 2001). Pharmacological study of the role of GluR-A subunit-containing AMPA receptors in the development of BZ tolerance is hampered by the lack of a selective ligand. Fortunately, a knockout mouse line has been generated in which the hippocampal LTP is abolished but the synaptic transmission remains largely unmodified (GluR-A−/− mice; Zamanillo et al., 1999). This defect in LTP is rescued by genetic re-expression of the GluR-A subunit (Mack et al., 2001). In the GluR-A−/− mice, chronic morphine administration leads to reduced tolerance and withdrawal symptoms, indicating an interaction between sedative opioid and excitatory glutamate neurotransmitter systems and highlighting the role of AMPA receptor mechanisms in the effects of addictive drugs (Vekovischeva et al., 2001).
Here we studied the effects of BZ flurazepam (FZ) at high doses in acute and chronic settings of tolerance and dependence in GluR-A−/− mice (Zamanillo et al., 1999). We used measurements in which the phenomenon of “learning while intoxicated” should play only a minor role in order to find out the significance of GluR-A subunit-containing AMPA receptors in the adaptation of the brain to the effects of high BZ levels.
Section snippets
Subjects
GluR-A−/− mice were produced by deletion of the Gria1 gene as described previously (Zamanillo et al., 1999). The mice were backcrossed to C57BL/6NHsd (Harlan BV., Horst, Netherlands) line seven times. In the experiments, male and female GluR-A−/− mice and their wild-type littermate controls were from heterozygous breeding, and all experiments were carried out at the age of 2.5–4 months. The animals were genotyped using tail-tip biopsy samples at the age of 30 days. The tails were digested
Acute effects of flurazepam
The GluR-A−/− mice were compared to their wild-type GluR-A+/+ littermates in regard to sensitivity to FZ (40 mg/kg) by assessing various behavioral parameters according to the SHIRPA protocol 30 min after the injection of the drug or saline. None of the measured parameters showed a difference between the genotypes (p > 0.05), except for the body temperature that was slightly lower in the knockouts (Fig. 1). The drug effect was clearly detected in all parameters (F1,69 > 9.95, p < 0.01). There were no
Discussion
Behavioral assessment of the effects of acute and subchronic treatment with FZ showed that the GluR-A subunit-deficient mouse line has a reduced capacity to develop tolerance to this drug. This result indicates that glutamatergic system has an important role in the neuroadaptation process opposing the increased neuronal inhibitory tone caused by BZs. However, precipitated withdrawal symptoms after the treatment were stronger in the GluR-A−/− mice, pointing to further differences in the
Acknowledgements
The present work was supported by the Finnish Foundation for Alcohol Studies (TA, ERK) and the Academy of Finland (ERK). The authors would like to thank Rolf Sprengel for providing the knockout mouse line, Jouko Laitila for excellent technical assistance, and Eeva Harju for checking the language of the manuscript.
References (42)
- et al.
Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence
Pharmacol Ther
(2003) - et al.
MK-801 prevents the increased NMDA-NR1 and NR2B subunits mRNA expression observed in the hippocampus of rats tolerant to diazepam
Brain Res
(2004) - et al.
Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse?
Trends Neurosci
(2002) - et al.
Neurobehavioral effects of alcohol in AMPA receptor subunit (GluR1) deficient mice
Neuropharmacology
(2003) - et al.
Validated method for the therapeutic drug monitoring of flunitrazepam in human serum using liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry with an ion trap detector
J Chromatogr B Biomed Sci Appl
(2000) - et al.
The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs
Prog Neurobiol
(1996) - et al.
Drug interactions at GABAA receptors
Prog Neurobiol
(2002) - et al.
Development of tolerance to the anticonvulsant effect of diazepam in amygdala-kindled rats
Exp Neurol
(1985) - et al.
Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons
Cell
(2001) - et al.
Selective enhancement of AMPA receptor-mediated function in hippocampal CA1 neurons from chronic benzodiazepine-treated rats
Neuropharmacology
(2002)
GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence?
Curr Opin Pharmacol
α-Amino-3-hydroxy-5-methylisoxazole-4-propionate receptor autoradiography in mouse brain after single and repeated withdrawal from diazepam
Eur J Neurosci
The drugs don't work-or do they? Pharmacological and transgenic studies of the contribution of NMDA and GluR-A-containing AMPA receptors to hippocampal-dependent memory
Psychopharmacology (Berl)
Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal
Curr Pharm Des
Flurazepam hydrochloride and its principal metabolites: behavioural studies in the monkey (Macaca mulatta)
Psychopharmacology (Berl)
Recovery from lorazepam tolerance and the effects of a benzodiazepine antagonist (RO 15–1788) on the development of tolerance
Psychopharmacology (Berl)
Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction
Science
Selective antagonists of benzodiazepines
Nature
Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse
Psychopharmacologia
Glutamic acid decarboxylase and glutamate receptor changes during tolerance and dependence to benzodiazepines
Proc Natl Acad Sci U S A
Learning mechanisms in addiction: synaptic plasticity in the ventral tegmental area as a result of exposure to drugs of abuse
Annu Rev Physiol
Cited by (10)
Biological behavior of 1, 4-benzodiazepines and 1, 4-benzothiazepines
2022, Benzodiazepine-Based Drug DiscoveryBenzodiazepine exposure induces transcriptional down-regulation of GABA<inf>A</inf> receptor α1 subunit gene via L-type voltage-gated calcium channel activation in rat cerebrocortical neurons
2020, Neuroscience LettersCitation Excerpt :Prolonged treatments with benzodiazepines have been shown to regulate the expression of NMDA and AMPA receptors [23,43]. AMPA-receptor GluR-A subunit-deficient mice exhibit reduced benzodiazepine tolerance [1]. NMDA antagonists prevent the development of tolerance to the sedative but not to the anxiolytic effects of benzodiazepines, suggesting different mechanisms [2].
Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740
2013, NeuroscienceCitation Excerpt :In the GluA1-KO hippocampus, excitatory synaptic transmission is slightly reduced (Andrasfalvy et al., 2003; Jensen et al., 2003; Romberg et al., 2009) and long-term potentiation impaired at the CA3-CA1 synapses (Zamanillo et al., 1999; Hoffman et al., 2002; Jensen et al., 2003; Romberg et al., 2009). The GluA1-KO mice display a repertoire of behavioral alterations including defective spatial working memory (Reisel et al., 2002; Schmitt et al., 2003), enhanced spatial long-term memory (Sanderson et al., 2009), increased depressive behavior (Chourbaji et al., 2008), defective prepulse inhibition (Wiedholz et al., 2008), abnormalities linked to psychoaffective disorders (Barkus et al., 2012), reduced aggression (Vekovischeva et al., 2004) and addiction/dependence-related phenotypes (Vekovischeva et al., 2001; Aitta-aho et al., 2009, 2012). A robust behavioral feature of the GluA1-KO mice is strong hyperlocomotion in response to a novel environment (Zamanillo et al., 1999; Vekovischeva et al., 2001; Procaccini et al., 2011).
Effects of chronic flunitrazepam treatment schedule on therapy-induced sedation and motor impairment in mice
2013, Pharmacological ReportsCitation Excerpt :Many studies have demonstrated GABAA receptor down regulation, following its exposure to BZ, what means that GABAA receptor's ability to bind BZ and enhance GABA neurotransmission is gradually reduced in time with BZ administration [3, 17, 26, 36]. Moreover, it is thought that excitatory mechanisms (such as the glutamatergic system) are sensitized to compensate for BZ-induced chronic enhancement of GABAergic inhibition [1, 2, 6]. The purpose of the reported study was to examine the effects of different treatment schedules on tolerance development to ataxic (motor impairing) and sedative effects of flunitrazepam (FNZ) in mice.
GABA<inf>A</inf> receptor subtypes and benzodiazepine use, misuse, and abuse
2023, Frontiers in Psychiatry